Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression Clinical Cancer Research Date: (2016) Targeting hypoxic prostate tumours using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant expression Ulster Medical Journal Date: (2016) Regulation of miR-200c and miR-141 by methylation in prostate cancer. Ulster Medical Journal Date: (2016) The role of miR-210 in Prostate Cancer tumour development Ulster Medical Journal Date: (2016) Regulation of miR-200c and miR-141 by methylation in prostate cancer The Prostate Date: (2016) Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition British Journal of Cancer Date: (2016) miR-24 regulates CDKN1B/p27 expression in prostate cancer. The Prostate Date: (2016) miR-24 regulates p27 expression in prostate cancer Ulster Medical Journal Date: (2015) Targeting hypoxia in prostate cancer cells to increase treatment efficacy Ulster Medical Journal Date: (2015) miR-24 regulates p27 expression in prostate cancer Date: (2015)